A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201

Rheumatoid Arthritis Clinical Trial

Official title:

A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00831649
• Other study ID #: ELN100226-RA251
• Status: Terminated
• Phase: Phase 2
• First received: January 27, 2009
• Last updated: June 14, 2016
• Start date: September 2004

Study information

• Verified date: January 2009
• Source: Biogen
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of natalizumab in subjects with active rheumatoid arthritis (RA) receiving concomitant methotrexate (MTX)

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 0
• Est. primary completion date: February 2005
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

INCLUSION CRITERIA

Subjects will be eligible to begin study participation if they meet all of the following inclusion criteria:

• Subjects must give written informed consent

• Male or female subjects =18 to =75 years of age (at randomization in Study ELN100226-RA201)

• Subjects must have been randomized in Study ELN100226-RA201;

• Subjects who have completed the Month 6 visit of Study ELN100226-RA201 OR Subjects who have an inadequate therapeutic response (defined as a < 20% reduction from baseline [Month 0 in Study ELN100226-RA201] for both painful/tender and swollen joint counts) after receiving at least 4 infusions of study drug and has not been rescued with other RA medications during the treatment phase of Study ELN100226-RA201;

• Subjects must be taking MTX at the same dose last used in Study ELN100226-RA201;

• Female subjects of childbearing potential agreed to use adequate, contraceptive methods (either intrauterine device [IUD], oral or depot contraceptive, or barrier plus spermicide). Female subjects of childbearing potential used adequate contraception for at least 2 months prior to study entry and continued contraception for at least 3 months after their last infusion of study drug;

• Subjects must be willing and able to complete all planned study procedures.

EXCLUSION CRITERIA

Subjects will be excluded from the study if they meet any of the following exclusion criteria:

• Females who are pregnant or breastfeeding or those planning to become pregnant in the next 14 months;

• Subjects who have experienced anaphylaxis, angioedema, urticaria, clinical syndrome diagnostic of serum sickness, or biopsy-proven vasculitis to a previous infusion of study drug;

• Subjects who received rescue intervention in Study ELN100226-RA201, defined as an increase in dose of an existing permitted concomitant treatment of RA or the introduction of a new treatment of RA;

• Subject who are expected to be unavailable for the duration of the trial, likely to be noncompliant with the Protocol, or who are felt to be unsuitable by the Investigator for any other reason;

• Subjects with a history of a malignancy (other than surgically excised basal or squamous cell carcinoma of the skin);

• Subjects with a history of clinically significant and/or persistent gastrointestinal, pulmonary, chronic infection, cardiovascular, renal, hepatic, neurological, dermatological, immunological, major psychiatric (including drug or alcohol abusers) or hematological illness, which in the opinion of the Investigator places the subject at unacceptable risk for participation in the study;

• Subjects who intend to donate blood or blood products during the period of the study or within one month following completion of the study.

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Rheumatoid Arthritis

Intervention

Drug:
• natalizumab

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Biogen	Elan Pharmaceuticals

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The number and proportion of subjects with AEs
Primary	The number and proportion of subjects with SAEs
Primary	The number and percentage of subjects who discontinue early from the study due to an AE
Primary	Assessment of clinical laboratory parameters, physical examination, and vital signs.